Last Updated: August 25, 2026

Details for Patent: 12,447,170

Name: Drug Patent Intelligence for US Patent 12447170
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 12,447,170 protect, and when does it expire?

Patent 12,447,170 protects LIVTENCITY and is included in one NDA.

This patent has twenty-one patent family members in nineteen countries.

Summary for Patent: 12,447,170

Title:	Use of maribavir in treatment regimens
Abstract:	Characterization of drug-drug interaction properties and pharmacological properties of maribavir is useful to inform potential drug-drug interactions and dosing strategies when administering with co-medications.
Inventor(s):	Heng Song, Kefeng SUN, Matthew Crouthamel, Grace Chen, Andy Z. X. ZHU, Ingrid Nicolle Michon, Howard James Burt, Zoe Elizabeth Barter, Sibylle Neuhoff
Assignee:	Takeda Pharmaceutical Co Ltd
Application Number:	US18/990,486
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 12,447,170

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	LIVTENCITY	maribavir	TABLET;ORAL	215596-001	Nov 23, 2021		RX	Yes	Yes	12,447,170	⤷ Start Trial				TREATING POST-TRANSPLANT CMV INFECTION/DISEASE REFRACTORY TO GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET BY ADMINISTERING 800 OR 1200 MG MARIBAVIR 2X DAILY WHERE PATIENT IS CONCOMITANTLY EXPOSED TO/RECEIVING ANTICONVULSANT, IMMUNOSUPPRESSANT	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 12,447,170

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2022395001	⤷ Start Trial
Australia	2025202348	⤷ Start Trial
Canada	3237758	⤷ Start Trial
China	118541156	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.